On 1 November 2017, Paola Arlotta focused on the cerebral cortex and presented the challenges and opportunities of modeling human brain development using pluripotent stem cells within 3D human brain organoids. Building on developmental work in mice, such organoids promise a better understanding of complex neurodevelopmental conditions such as autism spectrum disorder.
On 11 October 2017, David Ledbetter discussed the progress made by Geisinger Health System’s Precision Health Center – in partnership with Regeneron Genetics Center – towards advancing research and innovation by leveraging electronic health data and exome sequence data. Such an approach has already led to the successful identification of new drug targets and improved prevalence estimates of common Mendelian conditions, including familial hypercholesterolemia, BRCA-related cancers and Lynch syndrome, as well as autism spectrum and neuropsychiatric copy number variant disorders.
On 22 March 2017, Stephan Sanders presented an update on the current state of genetics research in autism, highlighting some of the key findings that remain to be discovered, and discussing how these findings could ultimately benefit individuals with autism and their families.
On 22 February 2017, Mark Zylka described how candidate environmental risk factors for autism can be identified rationally, by pinpointing chemicals that interfere with the same molecular pathways that are affected in individuals with autism.
On 1 February 2017, Arnold Kriegstein described recent advances in our understanding of the unique features of human cortical development and discussed insights into the origins of neurodevelopmental disorders.
On 25 January 2017, Jeremy Veenstra-VanderWeele outlined critical challenges to translating genomic, cellular, and animal model research into new treatments for autism spectrum disorder.